Drug intelligence / Profile preview

polymyxin b + gentamycin + amphotericin b

Development stage
Preclinical
Lead developer
SteriMax
Modality
Peptides, Small Molecules
Administration
Oral, Ophthalmic, Topical
01

Overview

This is a combination drug consisting of three active ingredients—polymyxin B, gentamicin, and amphotericin B. Each component has a distinct mechanism of action: - **Polymyxin B** is a polypeptide antibiotic that disrupts the cell membrane integrity of susceptible Gram-negative bacteria by binding to lipopolysaccharides and phospholipids in the outer cell membrane, leading to increased permeability and cell death[1]. - **Gentamicin** is an aminoglycoside antibiotic that binds irreversibly to the 30S subunit of bacterial ribosomes, inhibiting protein synthesis and causing misreading of mRNA in susceptible bacteria[3][5]. - **Amphotericin B** is an antifungal agent that binds to ergosterol in fungal cell membranes, forming pores that increase membrane permeability and result in leakage of intracellular components and fungal cell death[2]. This combination may be used for topical or local treatment where mixed infections (bacterial including Gram-negative organisms, as well as fungal) are suspected or confirmed.

Other names
polymyxin B + gentamycin + amphotericine B-MEDSI Clinical Hospital 1, ICU-ventilator-associated pneumonia-bloodstream infectionpolymyxin B + gentamycin + amphotericine BSelective Digestive Decontamination regimenSDD regimen
02

Targets

30S A-site (Bacterial ribosomal 30S A-site)Ergosterol

Beyond the preview

Go deeper on polymyxin b + gentamycin + amphotericin b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on polymyxin b + gentamycin + amphotericin b.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call